Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports
Go Back
View Our Subscription Options

Search

Descriptive Alt Text

Filters

Showing results 2,273–2,280 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Jazz Pharmaceuticals plc Zanidatamab + chemotherapy HER2-positive advanced or metastatic gastroesophageal adenocarcinoma Phase 2 Trial Completed Intravenous Oncology
Jazz Pharmaceuticals plc Defibrotide Sickle Cell Disease-Related Acute Chest Syndrome Phase 2 Data Released Intravenous Hematology
Johnson & Johnson TREMFYA (guselkumab) - (APEX) Active psoriatic arthritis BLA Filing Data Released Subcutaneous Immunology: Anti-TNF
Johnson & Johnson DARZALEX FASPRO / DARZALEX Subcutaneous monotherapy for highrisk smoldering multiple myeloma BLA Filing Ongoing Subcutaneous for DARZALEX FASPRO intravenous for DARZALEX Oncology
Johnson & Johnson TREMFYA (guselkumab) Pediatric Juvenile Psoriatic Arthritis BLA Filing Ongoing Subcutaneous Immunology: Anti-TNF
Johnson & Johnson TREMFYA (guselkumab) Pediatric Psoriasis BLA Filing Subcutaneous Immunology
Johnson & Johnson Amivantamab Non-small cell lung cancer (NSCLC) BLA Filing Intravenous Oncology
Johnson & Johnson CAPLYTA (Lumateperone) 42mg - (Study 304) Prevention of relapse in schizophrenia sNDA Filing Ongoing oral Psychiatric
1…283284285286287…553
Your trusted source for drug reimbursement data and buy-and-bill insights.
Platform
Resources
Tools
Search Drugs
Newsletter
Reimbursement updates, drug pricing news.
© 2026 BuyandBill.com, All Rights Reserved.
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association). CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.